Technology
Curocell’s OVIS™ technology enhances immune cells to overcome immune suppression in tumor microenvironments.
Our technology is evolving beyond the limitations of current immune cell therapies.
R&D
Pipeline 1
OVIS™ CD19 CAR-T
The next generation CD19 CAR-T, which is featured with innovative OVIS™ technology,
is expected more efficiently to treat lymphoma patients by overcoming the immune suppression.
Pipeline 2
OVIS™ BCMA CAR-T
The next generation BCMA CAR-T, which is featured with innovative OVIS™ technology,
is expected more efficiently to treat multiple myeloma patients by overcoming the immune suppression.
GMP Facility
Curocell produce the innovative immune cell product in GMP facility that complies with current regulation.
